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Abstract The direct conversion of simple and sterically
hindered Na-protected amino/peptide hydroxamic acids to
O-benzyl hydroxamates employing K2CO3, tetrabutylam-
monium bromide and benzyl bromide is described. In
addition, Cbz-Ala-CONHOH and Cbz-Phe-CONHOH
derived acylaminoxy peptides 3j and 3k have also been
prepared. The method is of importance in the view of easy
availability of precursors, catalyst and reaction conditions.
All the products are obtained in moderate to good yields.
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Introduction
The hydroxamic acid (RCONHOH) derivatives have
gained significance due to their wide variety of biological
functions including antibacterial, anticancer and antifungal
activity (Chimiak et al. 1988; Miller 1989, 1986; Weber
1983) and also their use as metal ion chelators. They can be
used in acylation reactions with loss of NO (Jung 2001).
They serve as inhibitors of metalloenzymes such as ther-
molysin (Whittaker et al. 1999). The hydroxamate func-
tionality is present in several natural products and in certain
siderophores such as ferrichrome, where it plays a unique
role in complexation of ferric ions (Emary T, In: Metal ions
in biological systems 1987). Suberoylanilide hydroxamic
acid (SAHA) is used for the treatment of cutaneous T cell
lymphoma along with the other potential pharmaceuticals
(Duvic and Vu 2007). Hydroxamic acids serves as pre-
cursors for the formation of peptide bond (Krishnamurthy
et al. 2015) through oxidation mediated by I2 and under-
goes Lossen rearrangement leading to carbamates, thio-
carbamates and ureas (Yoganathan and Miller 2003;
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Narendra et al. 2009; and Yadav et al. 2012). Tetrabuty-
lammonium bromide (TBAB) is an efficient homogeneous
catalyst for various functional group transformations
(Kantevari et al. 2008; Chary et al. 2008; Siddiqui et al.
2005; Ranu et al. 2002, 2003) which is water-tolerant, not-
expensive and eco-friendly.
Earlier approaches for the synthesis of O-benzyl
hydroxamates (Scheme 1) involve the treatment of
N-protected a-amino acid with O-benzyl hydroxylamine in
the presence of carbodiimide promoted condensation (Ra-
masamy et al. 1981). Gissot et al. (2005) synthesized O-
benzyl hydroxamates through a reaction involving unacti-
vated ester and O-benzyl hydroxamate. The reaction was
carried out at -75 C in the presence of lithium hexam-
ethyldisilazide (LiHMDS). Palakurthy et al. (2014) repor-
ted the reaction of carboxylic acid with O-benzyl
hydroxylamine in the presence of 1H-benzo[d][1,2,3]tria-
zole-1-yi-4-methanebenzenesulfonate (TsOBt) and N, N’-
diisopropylethylamine (DIPEA) leading to the desired
products. The same group reported another protocol which
comprise the reaction of carboxylic acid with O-benzyl
hydroxylamine, DIPEA and ethyl-2-cyano-2-(2-nitroben-
zenesulfonyloxyimino) acetate (O-NosylOXY) in CH2Cl2
(Dev et al. 2014). Pirrung and Chau (1995) accomplished
the synthesis of O-benzyl hydroxamates by initially treat-
ing trimethylaluminium with O-benzyl hydroxylamine in
toluene and then in situ reaction with an ester under reflux
in benzene. Some of these methods have certain limitations
such as use of corrosive and expensive reagents, low
temperature and long reaction duration.
Our group reported the synthesis of Fmoc-protected
amino acid hydroxamates from acid chlorides mediated by
magnesium oxide (Vasanthkumar and Sureshbabu 2003;
Nageswara and Sureshbabu 2014). Iodine/COMU-promoted
synthesis of Na-urethane protected amino/peptide hydrox-
amic acids was also reported by us (Nageswara et al. 2014).
A meticulous literature survey confirmed that direct con-
version of Na-protected hydroxamic acid to O-benzyl
hydroxamates is yet to be addressed. We herein present a
one pot protocol in which TBAB and K2CO3 can be suc-
cessfully utilized for the synthesis of Na-protected amino/
peptide O-benzyl hydroxamates and acylaminoxy peptides
using Na-protected hydroxamic acids and benzyl bromide. It
is simple, straight forward and inexpensive.
Experimental
Materials and Methods
All solvents were distilled through standard protocols
earlier to use. Amino acids and chemicals were used as
purchased from Sigma-Aldrich Company. All reactions
were monitored using TLCs (Merck silica gel 60F254
precoated aluminium plates purchased from merck). 1H
and 13C NMR spectra were recorded at 300 and 75 MHz
respectively, with CDCl3 as an internal standard. Mass
spectra were recorded using electron spray ionization mass
spectrometry (ESI–MS) and the samples were dried
through vacuum before analysis.
General Procedure for the Synthesis of Na-Protected
Amino/Peptide O-benzyl Hydroxamates, (3a–k and 5a–d)
To a solution of Na-protected amino/peptide hydroxamic
acid (1.0 equiv.), in THF (10 mL), K2CO3 (1.2 equiv.) and
15 mol% of tetrabutylammonium bromide (TBAB) was
added at 60 C. After 5–10 min, a solution of benzyl
Scheme 1 Literature survey for
the synthesis of O-benzyl
hydroxamates
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bromide/a-bromo acid (1.5 equiv.) in THF was added to
the reaction mixture then stirred for 45 min. The solvent
was removed under reduced pressure and the crude residue
was diluted with EtOAc (20 mL). The organic layer was
washed with 10 % HCl (15 mL), water (10 mL) and brine
solution (10 mL), dried over anhydrous Na2SO4 and
evaporated in vacuo. The crude residue was purified
through silica gel column chromatography (100–200
mesh), EtOAc/hexane (20:80) as eluent to obtain desired
products.
Characterization Data for the Compounds 3a–k and 5a–d
(S)-(9H-fluoren-9-yl)methyl (1-((benzyloxy)amino)-1-oxo-
propan-2-yl)carbamate (3a) 1H NMR (400 MHz, CDCl3):
d 1.32 (d, J = 3.2 Hz, 3H), 4.25-4.27 (m, 1H), 4.34 (t,
J = 8.8 Hz, 1H), 4.75 (d, J = 9.1 Hz, 2H), 4.85 (s, 2H),
5.45 (br s, 1H), 6.21 (br s, 1H), 7.25-7.90 (m, 13H); 13C
NMR (75 MHz, CDCl3): d 18.0, 47.2, 48.4, 67.3, 78.5,
119.7, 125.4, 127.1, 127.8, 128.7, 128.9, 129.1, 135.8,
141.7, 143.7, 156.0, 169.4 ppm; ESI–MS: m/z
[M ? H] ? calcd for C25H25N2O4; 417.18; found: 417.15.
(S)-(9H-fluoren-9-yl)methyl (1-((benzyloxy)amino)-1-oxo-3-
phenylpropan-2-yl)carbamate (3b) 1H NMR (300 MHz,
CDCl3): d 3.09–3.14 (m, 2H), 4.15–4.19 (m, 1H), 4.32 (t,
J = 6.0 Hz, 1H), 4.52 (d, J = 6.0 Hz, 2H), 4.79 (s, 2H),
5.32 (br s, 1H), 6.01 (br s, 1H), 7.23–7.92 (m, 18H); 13C
NMR (75 MHz, CDCl3): d 38.4, 47.2, 53.4, 67.1, 78.3,
120.1, 125.0, 125.5, 126.0, 126.2, 127.2, 127.5, 127.7,
128.7, 128.9, 135.5, 135.7, 141.3, 143.8, 156.7, 169.2 ppm;
ESI–MS: m/z [M?H]? calcd for C31H29N2O4; 493.20;
found: 493.18.
(S)-(9H-fluoren-9-yl)methyl (1-((benzyloxy)amino)-3-methyl-
1-oxobutan-2-yl)carbamate (3c) 1H NMR (300 MHz,
CDCl3): d 0.93 (d, J = 5.0 Hz, 6H), 2.05-2.10 (m, 1H), 4.
20-4.25 (m, 1H) 4.35 (t, J = 3.4 Hz, 1H), 4.43 (d,
J = 5.0 Hz, 2H), 4.82 (s, 2H), 5.18 (br s, 1H), 6.32 (br s,
1H), 7.27-7.82 (m, 13H); 13C NMR (75 MHz, CDCl3): d
18.5, 31.2, 47.0, 57.8, 67.1, 78.5, 120.3, 125.0, 126.5,
127.3, 128.3, 128.9, 129.3, 135.3, 141.4, 143.5, 156.2,
168.9 ppm; ESI–MS: m/z [M?H]? calcd for C27H29N2O4;
445.21; found: 445.19.
(S)-(9H-fluoren-9-yl)methyl (2-((benzyloxy)amino)-2-oxo-
1-phenylethyl)carbamate (3d) 1H NMR (300 MHz,
CDCl3): d 4.19–4.21 (m, 1H), 4.38 (t, J = 3.0 Hz, 1H),
4.51 (d, J = 3.0 Hz, 2H), 4.75 (s, 2H), 5.16 (br s, 1H),
7.21–7.40 (m, 18H), 8.52 (br s, 1H); 13C NMR (75 MHz,
CDCl3): d 47.0, 56.4, 67.3, 78.0, 120.2, 125.3, 126.2,
127.0, 127.1, 127.5, 127.6, 128.5, 129.2, 129.5, 136.5,
136.8, 142.5, 143.6, 156.4, 166.0 ppm; ESI–MS: m/z
[M?H]? calcd for C30H27N2O4; 479.19; found: 479.18.
(S)-(9H-fluoren-9-yl)methyl (1-((benzyloxy)amino)-4-methyl-
1-oxopentan-2-yl)carbamate (3e) 1H NMR (300 MHz,
CDCl3): d 0.87 (d, J = 3.0 Hz, 6H), 1.44–1.46 (m, 1H),
1.56–1.58 (m, 2H), 4.10–4.12 (m, 1H), 4.39 (t, J = 6.0 Hz,
1H), 4.48 (d, J = 6.0 Hz, 2H), 4.65 (s, 2H), 5.35 (br s, 1H),
7.19-7.48 (m, 13H), 9.48 (br s, 1H); 13C NMR (75 MHz,
CDCl3): d 22.9, 24.6, 41.2, 47.1, 50.5, 67.1, 78.3, 120.5,
125.2, 127.1, 127.1, 127.4, 128.2, 128.5, 135.3, 141.5,
143.7, 156.4, 169.7 ppm; ESI–MS: m/z [M?H]? calcd for
C28H31N2O4; 459.22; found: 459.19.
(S)-benzyl 3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-
4-((benzyloxy)amino)-4-oxobutanoate (3f) 1H NMR
(300 MHz, CDCl3): d 2.96–2.98 (m, 2H), 4.22–4.24 (m,
1H), 4.38 (t, J = 6.0 Hz, 1H), 4.45 (d, J = 3.0 Hz, 2H),
4.51 (s, 2H), 4.85 (s, 2H), 5.61 (br s, 1H), 7.22-7.69 (m,
18H), 8.89 (br s, 1H); 13C NMR (75 MHz, CDCl3): d 36.1,
47.0, 50.8, 66.5, 67.3, 78.4, 119.5, 125.2, 126.0, 126.4,
126.9, 127.1, 128.5, 135.8, 136.4, 155.8, 169.4, 171.2 ppm;
ESI–MS: m/z [M?H]? calcd for C33H31N2O6; 551.21;
found: 551.19.
(S)-benzyl (1-((benzyloxy)amino)-1-oxo-3-phenylpropan-2-
yl)carbamate (3g) 1H NMR (300 MHz, CDCl3): d
3.14–3.17 (m, 2H), 3.88–3.91 (m, 1H), 4.72 (s, 2H), 5.04
(s, 2H), 5.26 (br s, 1H), 7.17–7.38 (m, 15H), 8.54 (br s,
1H); 13C NMR (75 MHz, CDCl3): d 37.0, 54.8, 66.7, 78.2,
125.6, 126.8, 127.5, 127.7, 128.2, 128.7, 136.1, 136.5,
136.6, 155.9, 169.4 ppm; ESI–MS: m/z [M?H]? calcd for
C24H25N2O4; 405.18; found: 405.15.
(S)-benzyl (1-((benzyloxy)amino)-3-methyl-1-oxobutan-2-
yl)carbamate (3h) 1H NMR (300 MHz, CDCl3): d 0.97
(d, J = 3.0 Hz, 6H), 2.13–2.14 (m, 1H), 4.07–4.11 (m,
1H), 4.85 (s, 2H), 5.09 (s, 2H), 5.22 (br s, 1H), 7.24–7.37
(m, 10H), 8.96 (br s, 1H); 13C NMR (75 MHz, CDCl3): d
18.5, 18.6, 29.8, 60.2, 66.8, 78.5, 127.1, 127.5, 128.9,
136.2, 136.5, 155.6, 168.7 ppm; ESI–MS: m/z [M?H]?
calcd for C20H25N2O4; 357.18; found: 357.14.
(S)-tert-butyl (1-((benzyloxy)amino)-1-oxopropan-2-yl)carba-
mate (3i) 1H NMR (300 MHz, CDCl3): d 1.41 (s, 9H),
1.35 (d, J = 6.0 Hz, 3H), 4.02–4.04 (m, 1H), 4.78 (s, 2H),
5.08 (br s, 1H), 7.38–7.45 (m, 5H), 9.38 (br s, 1H); 13C
NMR (75 MHz, CDCl3): d 17.8, 28.5, 50.2, 78.3, 80.1,
127.1, 127.6, 128.5, 135.8, 156.1, 169.4 ppm; ESI–MS:
m/z [M?H]? calcd for C15H23N2O4; 295.16; found:
295.14.
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(R)-5-methyl-3,6-dioxo-1-phenyl-2,8-dioxa-4,7-diazade-
can-10-oic acid (3j) 1H NMR (300 MHz, CDCl3): d 1.36
(d, J = 3.0 Hz, 3H), 4.28–4.40 (m, 1H), 4.59 (s, 2H), 5.08
(s, 2H), 5.18 (br s, 1H), 5.75 (br s, 1H), 7.28–7.50 (m, 5H),
10.22 (br s, 1H); 13C NMR (75 MHz, CDCl3): d 17.0, 50.6,
66.7, 68.9, 127.1, 127.6, 128.6, 135.8, 155.7, 169.2,
172.8 ppm; ESI–MS: m/z [M?Na]? calcd for C13H16N2-
O6Na; 319.09; found: 319.06.
(R)-5-benzyl-3,6-dioxo-1-phenyl-2,8-dioxa-4,7-diazadecan-
10-oic acid (3k) 1H NMR (300 MHz, CDCl3): d 3.08-
3.25 (m, 2H), 4.68–4.75 (m, 1H), 4.69 (s, 2H), 5.10 (s, 2H),
5.26 (br s, 1H), 6.08 (br s, 1H), 7.20–7.39 (m, 10H), 10.34
(br s, 1H); 13C NMR (75 MHz, CDCl3): d 37.3, 55.1, 66.8,
77.1, 125.8, 126.8, 127.5, 127.8, 128.6, 128.8, 136.1,
136.6, 155.9, 169.4 172.0 ppm; ESI–MS: m/z [M?Na]?
calcd for C19H20N2O6Na; 395.12; found: 395.08.
(9H-fluoren-9-yl)methyl ((S)-1-(((S)-1-((benzyloxy)amino)-
1-oxo-3-phenylpropan-2-yl)amino)-1-oxopropan-2-yl)car-
bamate (5a) 1H NMR (300 MHz, CDCl3): d 1.34 (d,
J = 3 Hz, 3H), 3.18–3.24 (m, 2H), 4.08–4.11 (m, 1H),
4.18–4.22 (m, 1H), 4.32 (t, J = 9 Hz, 1H), 4.34 (d,
J = 6 Hz, 2H), 4.75 (s, 2H), 5.42 (br s, 1H), 6.52 (br s,
1H), 7.08–7.76 (m, 18H), 8.76 (br s, 1H); 13C NMR
(75 MHz, CDCl3): d 17.5, 38.0, 46.8, 52.6, 53.8, 67.1,
78.7, 120.5, 124.8, 125.6, 126.2, 126.8, 127.0, 127.5,
127.7, 128.5, 128.8, 135.8, 136.5, 142.1, 143.8, 156.1,
170.4, 173.6 ppm; ESI–MS: m/z [M?H]? calcd for
C34H34N3O5; 564.24; found: 564.18.
Benzyl ((S)-1-(((S)-1-((benzyloxy)amino)-1-oxopropan-2-
yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate (5b) 1H
NMR (300 MHz, CDCl3): d 1.30 (d, J = 6 Hz, 3H),
2.91–3.22 (m, 2H), 4.37–4.40 (m, 1H), 4.52–4.55 (m, 1H),
4.71 (s, 2H), 5.08 (s, 2H), 5.32 (br s, 1H), 6.45 (br s, 1H),
7.19–7.42 (m, 15H), 8.56 (br s, 1H); 13C NMR (75 MHz,
CDCl3): d 18.1, 37.9, 49.1, 57.9, 67.0, 78.9, 125.9, 126.2,
127.1, 127.4, 127.6, 127.7, 128.6, 128.7, 128.9, 136.1,
136.4, 136.5, 155.9, 171.5, 172.8 ppm; ESI–MS: m/z
[M?H]? calcd for C27H30N3O5; 476.21; found: 476.19.
(S)-benzyl (1-((2-((benzyloxy)amino)-2-oxoethyl)amino)-1-
oxopropan-2-yl)carbamate (5c) 1H NMR (300 MHz,
CDCl3): d 1.34 (d, J = 3 Hz, 3H), 4.01–4.13 (m, 3H), 4.79
(s, 2H), 5.10 (s, 2H), 5.32 (br s, 1H), 6.49 (s, 1H), 7.19–7.40
(m, 10H), 8.98 (br s, 1H); 13C NMR (75 MHz, CDCl3): d
17.1, 38.7, 54.3, 66.4, 78.5, 125.4, 126.8, 127.1, 127.5, 128.2,
128.6, 135.8, 136.4, 156.2, 169.0, 172.2 ppm; ESI–MS: m/z
[M?H]? calcd for C20H24N3O5; 386.16; found: 386.14.
Tert-butyl ((S)-1-(((S)-1-((benzyloxy)amino)-1-oxo-3-phenyl-
propan-2-yl)amino)-1-oxopropan-2-yl)carbamate (5d) 1H
NMR (300 MHz, CDCl3): d 1.20 (d, J = 3 Hz, 3H), 1.38
(s, 9H), 3.15–3.20 (m, 2H), 4.35–4.39 (m, 1H), 4.57–4.60
(m, 1H), 4.85 (s, 2H), 5.12 (br s, 1H), 6.38 (br s. 1H),
7.29–7.51 (m, 10H), 9.02 (br s, 1H); 13C NMR (75 MHz,
CDCl3): d 17.5, 28.4, 37.4, 53.2, 53.9, 78.4, 79.5, 126.1,
127.1, 127.4, 127.7, 128.5, 128.9, 136.5, 136.6, 155.8,
Scheme 2 Synthesis of Na–protected hydroxamic acids 1
Table 1 Synthesis of Na-protected O-benzyl hydroxamates 3a: Optimization of reaction conditions
Entry Catalyst (mol%) Solvent Base (equiv.) Temp (oC) Time Yield (%)a
1 – THF K2CO3 (1.2) r.t 12 h 20
2 – THF K2CO3 (1.2) 60 4 h 60
3 – DCM K2CO3 (1.2) 35 4 h 55
4 – MeCN K2CO3 (1.2) 70 4 h 50
5 – THF Pyridine (2.0) 60 4 h 31
6 – THF Et3N (2.0) 60 4 h 45
7 TBAB (15) THF K2CO3 (1.2) 60 45 min 96
8 TEAB (15) THF K2CO3 (1.2) 60 45 min 72
9 CTAB (15) THF K2CO3 (1.2) 60 45 min 79
a Yields corresponding to the isolated pure products
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170.1, 171.7 ppm; ESI–MS: m/z [M?H]? calcd for
C24H32N3O5; 442.23; found: 442.19.
Results and Discussions
The starting compound for the present study was Na-pro-
tected hydroxamic acids 1whichwere obtained by following
our reported protocol (Vasantha et al. 2010). Briefly, Na-
protected carboxylic acid was activated employing an
equimolar quantity of T3P (Propylphosphonic anhydride) in
acetonitrile in the presence of N-methylmorpholine (NMM)
at 0 C for 15 min, followed by the addition of hydroxy-
lamine under ultra-sonication for about 30 min afforded the
desired product (Scheme 2). Another starting component
benzyl bromide 2 is commercially available.
In our preliminary attempt, in a reaction between Fmoc-
Ala-CONHOH 1a and benzyl bromide 2a in the presence
of K2CO3 in dry THF at room temperature gave 3a in 20 %
yield (Table 1, entry 1). To improve the yield, the reaction
was carried out by using different solvents (THF, DCM and
MeCN) and bases (K2CO3, Et3N and pyridine). The tem-
perature was also varied from r.t to 60 C. The results of
this study are furnished in Table 1. Entry 2 shows that at
60 C in dry THF for 4 h in the presence of K2CO3 resulted
3a in 60 % yield. When reaction carried out in DCM and
MeCN under reflux lead to increase the yield of 3a
(50–55 %), but still not satisfactory (Entries 3 and 4).
Entries 5 and 6 illustrates that 3a was formed in low yields
31 and 45 % through the use of pyridine and Et3N in dry
THF at reflux respectively. By adding 15 mol% of TBAB
to the reaction mixture, rapid formation of Na-protected O-
benzyl hydroxamates in 96 % yield was recorded. The
reaction duration was reduced to 45 min (Entry 7). Further,
in addition to TBAB, other two phase transfer catalysts like
tetraethylammonium bromide (TEAB) and cetyltrimethy-
lammonium bromide (CTAB) have been tried (Entries 8
and 9). Among these, it was confirmed that TBAB is an
efficient one for the completion of reaction with good yield
in short duration. Both the nature of the catalyst and
reaction medium significantly affected the rate of reaction.
Having the optimal reaction conditions in hand, the
scope of the protocol is exemplified with a series of simple
and sterically hindered Na–protected hydroxamic acids (1.0
equiv.). The reaction was thus carried out using K2CO3
(1.2 equiv.) and 15 mol% of TBAB in THF at 60 C. After
5–10 min, benzyl bromide (1.2 equiv.) was added. The
reaction was found to be complete in 45 min, as monitored
by TLC analysis. A simple work-up followed by purifica-
tion through column chromatography [EtOAc: hexane],
resulted in pure Na-protected O-benzyl hydroxamates (3a–
i) in good yields. Further, this protocol was extended to
synthesize acylaminoxy dipeptides 3j and 3k (Scheme 3;
Fig. 1). Presumably, the bromide ion of TBAB readily
forms hydrogen bonding to the hydroxyl (NHOH)
increasing the nucleophilicity of oxygen atom. This makes
the oxygen anion a better nucleophile. All compounds
made were characterized by mass, 1H and 13C NMR
analysis.
Scheme 3 The synthesis of Na-protected O-benzyl hydroxamates
3a–i, acylaminoxy dipeptides 3j and 3k
Fig. 1 List of Na-protected O-
benzyl hydroxamates 3a–i,
acylaminoxy dipeptides 3j and
3k from hydroxamic acids
(aPalakurthy et al. 2014; bDev
et al. 2014 and cKatritzky et al.
2009)
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As a part of this study, the synthesis of Na-protected
peptide O-benzyl hydroxamates 5 was also carried out
employing the above protocol. In a typical experiment,
Fmoc-Ala-Phe-w[CONHOH] (1.0 equiv.) 4a in dry THF
was made to react with K2CO3 (1.2 equiv.) and 15 mol% of
TBAB at 60 C. After 5–10 min, benzyl bromide (1.2
equiv.) 2a was added to the reaction mixture. The reaction
was found to be complete in about 45 min (as monitored by
TLC analysis). A simple work up followed by purification
of the crude product through column chromatography gave
the pure Na-protected peptide O-benzyl hydroxamates 5a
(Scheme 4).
The generality of the above method was established by
synthesizing four Na-protected peptide O-benzyl hydroxa-
mates 5a–d employing Fmoc/Cbz/Boc-protected peptide
hydroxamic acids and benzyl bromide. All compounds
were obtained in good yields as furnished in Fig. 2, which
were then characterized.
Conclusion
In summary, we report a simple, mild and efficient protocol
for the synthesis of Na-protected amino/peptide O-benzyl
hydroxamates and acylaminoxy dipeptides employing
K2CO3 and TBAB as a catalyst. This protocol results in
significant improvements in yields of the products.
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